Stay updated on Apremilast-Dupilumab Combo in Eczema Clinical Trial
Sign up to get notified when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.

Latest updates to the Apremilast-Dupilumab Combo in Eczema Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedUpdates the ClinicalTrials.gov page revision indicator from v3.5.2 to v3.5.3 without changing the study content shown in the record.SummaryDifference0.1%

- Check27 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check56 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check92 days agoChange DetectedThe page now displays Revision: v3.4.2. The funding-status notice has been removed (the previous Revision: v3.4.1 was deleted).SummaryDifference0.5%

- Check99 days agoChange DetectedAdded a funding-status notice at the top of the page about potential data currency issues and a Revision banner showing v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Apremilast-Dupilumab Combo in Eczema Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.